Search

Purpose: Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL patients treated with and without long-acting pegylated asparaginase (PegA)., Methods: Single-center, retrospective analysis of 89 ALL patients treated with (n = 61) or without (n = 28) PegA at Greenebaum Comprehensive Cancer Center. Reviewed patient and disease characteristics, treatment, and VTE incidence., Results: VTE during treatment occurred in 31 patients (35%), and was associated with PegA (p = 0.001) and Philadelphia chromosome negativity (p = 0.002). Among PegA recipients, VTE was associated with a significantly higher mean body mass index (BMI) of 31.3 kg/m 2 (p = 0.037), and was more common with pre-T/T cell compared to pre-B/B cell ALL (68.2% vs. 33.3%, p = 0.009). Antithrombin-III (ATIII) levels were measured for 26 patients; 16 (61.5%) were < 50%. Of those, 8 (50%) experienced VTE, while 3 of 10 (30%) patients with ATIII levels ≥ 50% experienced VTE. VTE occurred in 7 of 13 (54%) of patients who received ATIII repletion. There was a trend toward a higher incidence of VTE in the PegA group among patients with non-O compared to O blood type (55.9% vs. 33.3%, p = 0.079) as well as those with a higher hemoglobin at diagnosis (9.3 vs 8.1 g/dL, p = 0.056)., Conclusion: This study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain.

Introduction: Obesity has become increasingly prevalent worldwide and is a risk factor for many malignancies. We studied the correlation between body mass index (BMI) and the incidence of acute promyelocytic leukemia (APL), non-APL acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and control hospitalized patients without leukemia in the same community., Methods: Multi-center, retrospective analysis of 71,196 patients: APL (n=200), AML (n=437), ALL (n=103), non-leukemia hospitalized (n=70,456) admitted to University of Maryland and Johns Hopkins Cancer Centers, and University of Maryland Medical Center., Results: Patients with APL had a significantly higher unadjusted mean and median BMI (32.5 kg/m 2 and 30.3 kg/m 2 ) than those with AML (28.3 kg/m 2 and 27.1 kg/m 2 ), ALL (29.3 kg/m 2 and 27.7 kg/m 2 ), and others (29.3 kg/m 2 and 27.7 kg/m 2 ) (p<0.001). Log-transformed BMI multivariable models demonstrated that APL patients had a significantly higher adjusted mean BMI by 3.7 kg/m 2 (p<0.001) or approximately 10% (p<0.01) compared to the other groups, when controlled for sex, race, and age., Conclusions: This study confirms that when controlled for sex, age, and race there is an independent association of higher BMI among patients with APL compared to patients with ALL, AML, and hospitalized individuals without leukemia in the same community., Competing Interests: Conflicts of Interest: All authors declare that they do not have relevant competing interests.

Background: Numerous signalized intersections worldwide have been equipped with enforcement cameras in order to tackle red light running and often also to enforce speed limits. However, various impact evaluation studies of red light cameras (RLCs) showed an increase of rear-end collisions (up to 44%)., Objective: The principal objective of this study is to provide a better insight in possible explaining factors for the increase in rear-end collisions that is caused by placing combined speed and red light cameras (SRLCs)., Method: Real-world observations and driving simulator-based observations are combined. Video recordings at two signalized intersections where SRLCs were about to be installed are used to analyze rear-end conflicts, interactions and driver behavior in two conditions (i.e., with and without SRLC). Furthermore, one of these intersections was rebuilt in a driving simulator equipped with an eye tracking system. At this location, two test conditions (i.e., SRLC and SRLC with a warning sign) and one control condition (i.e., no SRLC) are examined. The data of 63 participants were used to estimate the risk of rear-end collisions by means of a Monte Carlo Simulation., Results: The results of the on-site observation study reveal decreases in the number of red and yellow light violations, a shift (i.e., closer to the stop line) in the dilemma zone and a time headway reduction after the installation of the SRLC. Based on the driving simulator data, the odds of rear-end collisions (compared to the control condition) for the conditions with SRLC and SRLC+warning sign is 6.42 and 4.01, respectively., Conclusion: The real-world and driving simulator observations indicate that the risk of rear-end collisions increases when SRLCs are installed. However, this risk might decrease when a warning sign is placed upstream., (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Colimycin is sulfomethylated in order to inactivate it temporarily in vivo. In vitro, this process may have unexpected results because the experiment is carried out within a closed system. The time required to activate the antibiotic varies according to incubation conditions. The freed sulfomethyl groups are probably eliminated in vivo. In vitro, these residues may interact with the outer membrane of Escherichia coli B which is charged with badly positioned molecules of colimycin, thus creating a barrier for the active molecules. As the expected mechanism of polymyxin B or E action include first electrostatic interactions, it is not surprising that a modification of the ionic balance of the medium should be of such importance.